calprotectin

calprotectin

(kăl″prō-tĕk′tĭn)
A water-soluble, 36.5 kD protein found in the cytosol of neutrophils. Laboratory assays that detect fecal calprotectin (FC) are used as screening tests for colorectal cancer, diverticulitis, dysentery, and inflammatory bowel diseases. FC levels are not elevated in patients with functional or noninflammatory bowel disorders.
Mentioned in ?
References in periodicals archive ?
We believe the Phase 1 clinical results reinforced BT-11's benign safety profile and showed a response to treatment based on lower concentrations of fecal calprotectin, which we believe is a predictive biomarker of therapeutic response and extended clinical remission in inflammatory bowel disease (IBD).
Fecal calprotectin levels, which the company believes is a predictive biomarker of response to treatment in IBD, were lower in all BT-11-treated groups when compared to placebo.
Increased levels of calprotectin in obesity are related to macrophage content: impact on inflammation and effect of weight loss.
The BUHLMANN fCAL[R] turbo is an in vitro diagnostic assay intended for the quantitative measurement of fecal calprotectin (fCAL), a neutrophilic protein that is a marker of intestinal mucosal inflammation, in human stool.
The conducted stool tests were three times negative for parasites and the calprotectin level was within normal limits.
Two additional markers, lactoferrin and calprotectin, are increased in inflammatory bowel disease but not in irritable bowel syndrome.
Contract notice: supply of reagents, consumables and assignment of equipment for the determination of calprotectin in faeces in huse clinical analysis laboratory
CRP, IL-6, tumor necrosis factor, PCT, granulocyte colony-stimulating factor, calprotectin, chemokine ligand-8, serum amyloid A, matrix metalloproteinase 9, and myeloperoxidase are among the inflammatory markers investigated (7,11).
Could "calprotectin" and "endocan" serve as "Troponin of Nephrologists"?
At the primary care level noninvasive tests such as fecal calprotectin can help identify patients with inflammatory conditions and "more rapid access to gastroenterologists for earlier diagnosis of IBD can improve patient outcomes," said gastroenterologist and study lead author Zane Gallinger, MD, FRCPC, of the University of Toronto at Mount Sinai Hospital, in an interview.
Interestingly, ACT did not significantly improve symptom burden, activities of daily living, disease-related worry, general well-being, C-reactive protein (CRP) levels, fecal calprotectin levels, or scores on the version used of the Clinical Assessment of Depression (CAD) or the short Mayo assessment.
lysozyme, calprotectin, lactoferrin), and mucus (shedding) in stool specimens.